

WORLD HEALTH ORGANIZATION
STRATEGIC AND TECHNICAL ADVISORY GROUP
FOR NEGLECTED TROPICAL DISEASES
WORKING GROUP ON MONITORING AND EVALUATION

DESIGN AND VALIDATION
OF A TRACHOMATOUS TRICHIASIS-ONLY SURVEY



World Health
Organization

Design and validation of a trachomatous trichiasis-only survey

Strategic and Technical Advisory Group for Neglected Tropical Diseases

Working Group on Monitoring and Evaluation



WHO/HTM/NTD/PCT/2017.08

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Design and validation of a trachomatous trichiasis-only survey. Geneva: World Health Organization ; 2017 (WHO/HTM/NTD/PCT/2017.08). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Abbreviations.....	iv
Acknowledgements.....	v
1. Background	1
2. Simulations with existing data	2
3. Conjunctival scarring, and lower lid trichiasis.....	5
4. Draft design.....	5
5. Validating the draft design: precision	6
6. Validating the draft design: cost	13
7. Discussion.....	15
8. Recommendations	16
References	17

Abbreviations

TF	trachomatous inflammation—follicular
TT	trachomatous trichiasis
TS	trachomatous scarring
WHO	World Health Organization

Acknowledgements

This report was prepared by Rebecca Mann Flueckiger, Paul Courtright, David C. W. Mabey, Rachel L. Pullan and Anthony W. Solomon.

Field work was conducted by the health ministries of Cameroon, Chad, Uganda and the United Republic of Tanzania. Support to and supervision of fieldwork was provided by Lucienne Bella Assumpta, Gilbert Baayenda, Jérôme Bernasconi, Epée Emilienne, George Kabona, Mathias Kamugisha, Edward Kirumbi, Upendo Mwingira, Jeremiah Ngondi and Patrick Turyaguma.

Christopher Fitzpatrick, Katherine Gass, Charles Opondo and Rebecca Willis contributed to methodological development and data analysis.

1. Background

1.1 The Fifty-first World Health Assembly adopted resolution WHA51.11 in 1998, which targets the global elimination of trachoma as a public health problem by 2020 (1). The strategy recommended to achieve that goal is encapsulated by the acronym “SAFE”, which represents: Surgery for individuals with trachomatous trichiasis (TT; the late blinding stage of trachoma); and Antibiotics, Facial cleanliness and Environmental improvement (2). The A, F and E interventions are delivered to entire districts in which active (inflammatory) trachoma is common in order to treat ocular infection with *Chlamydia trachomatis*, the causative organism of trachoma, and sustainably reduce its transmission.

1.2 At a series of global scientific meetings on trachoma (3–6), elimination thresholds for trachoma were defined as a prevalence of the active trachoma sign “trachomatous inflammation—follicular” (TF) (7) of < 5% in children aged 1–9 years, and a prevalence of TT (7) unknown to the health system of < 0.2% in adults aged ≥ 15 years (8). The prevalence of these signs should be measured at district level, where districts are “the administrative unit for health care management”, which “for purposes of clarification, consists of a population unit between 100 000–250 000 persons” (5).

1.3 The World Health Organization (WHO) endorses the use of population-based prevalence surveys for estimating the prevalence of trachoma (9). In general, the prevalence of TF in children aged 1–9 years and the prevalence of TT in adults aged ≥ 15 years are measured at the same time in any district being surveyed. This was the approach of the Global Trachoma Mapping Project (10), which undertook baseline surveys in > 1500 districts worldwide in order to provide the data required to start interventions where needed (11).

1.4 The survey design recommended by WHO is a two-stage cluster random sample survey, which uses probability proportional to size sampling to select 20–30 villages (9), and random, systematic or quasi-random sampling to select 25–30 households in each of those villages (10). In most surveys, everyone aged ≥ 1 year living in selected households is examined.

1.5 Usually, surveys are powered to estimate the prevalence of TF in 1–9-year-olds (9,10). TF is most common in young children, whereas TT becomes increasingly common with increasing age (12–15); it is also, in the population as a whole, a much less common sign than TF. Because of this, and because the number of adults aged ≥ 15 years resident in a group of selected households is often not much more than the number of 1–9-year-olds resident in those households, the number of adults examined in a survey is generally not sufficient for estimating TT prevalence with good precision. These surveys simply accept poor precision in estimating TT (6,9,10).

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/repor>